174 related articles for article (PubMed ID: 37058053)
1. Construction of an m6A-related lncRNA model for predicting prognosis and immunotherapy in patients with lung adenocarcinoma.
Shen HY; Zhang J; Xu D; Xu Z; Liang MX; Chen WQ; Tang JH; Xia WJ
Medicine (Baltimore); 2023 Apr; 102(15):e33530. PubMed ID: 37058053
[TBL] [Abstract][Full Text] [Related]
2. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
Zhao J; Lin X; Zhuang J; He F
Front Genet; 2021; 12():714697. PubMed ID: 34777460
[No Abstract] [Full Text] [Related]
3. Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis.
Gao C; Kong N; Zhang F; Zhou L; Xu M; Wu L
BMC Bioinformatics; 2022 Aug; 23(1):327. PubMed ID: 35941550
[TBL] [Abstract][Full Text] [Related]
4. Construction of a lung adenocarcinoma prognostic model based on N6-methyl-adenosine-related long noncoding RNA and screening of potential drugs based on this model.
Hou Q; Zhong Y; Liu L; Wu L; Liu J
Anticancer Drugs; 2022 Apr; 33(4):371-383. PubMed ID: 35213857
[TBL] [Abstract][Full Text] [Related]
5. Integrated analysis on the N6-methyladenosine-related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma.
Qiu Y; Wang X; Fan Z; Zhan S; Jiang X; Huang J
Immun Inflamm Dis; 2021 Dec; 9(4):1596-1612. PubMed ID: 34432955
[TBL] [Abstract][Full Text] [Related]
6. Risk stratification of lung adenocarcinoma using a nomogram combined with ferroptosis-related LncRNAs and subgroup analysis with immune and N6-methyladenosine modification.
Gao C; Kong N; Zhang F; Tang T; Li J; Ding H; Sun Z; Wu L; Xu M
BMC Med Genomics; 2022 Jan; 15(1):15. PubMed ID: 35093068
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel m6A-related lncRNA pair signature for predicting the prognosis of gastric cancer patients.
Wang JM; Li X; Yang P; Geng WB; Wang XY
BMC Gastroenterol; 2022 Feb; 22(1):76. PubMed ID: 35189810
[TBL] [Abstract][Full Text] [Related]
8. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
[TBL] [Abstract][Full Text] [Related]
9. A Novel m6A-Related LncRNA Signature for Predicting Prognosis, Chemotherapy and Immunotherapy Response in Patients with Lung Adenocarcinoma.
Shen Y; Wang S; Wu Y
Cells; 2022 Aug; 11(15):. PubMed ID: 35954243
[TBL] [Abstract][Full Text] [Related]
10. m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer.
Feng ZH; Liang YP; Cen JJ; Yao HH; Lin HS; Li JY; Liang H; Wang Z; Deng Q; Cao JZ; Huang Y; Wei JH; Luo JH; Chen W; Chen ZH
J Transl Med; 2022 Oct; 20(1):492. PubMed ID: 36309694
[TBL] [Abstract][Full Text] [Related]
11. Analysis of N6-methyladenosine-related lncRNAs in the tumor immune microenvironment and their prognostic role in pancreatic cancer.
Liu Y; Wang T; Fang Z; Kong J; Liu J
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1613-1626. PubMed ID: 35314871
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarcinoma.
Li XQ; Yin SQ; Chen L; Tulamaiti A; Xiao SY; Zhang XL; Shi L; Miao XC; Yang Y; Xing X
BMC Cancer; 2024 Jan; 24(1):116. PubMed ID: 38262966
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of N6-Methyladenosine-Related lncRNAs in Early-Stage Colorectal Cancer: Association With Immune Cell Infiltration and Chemotherapeutic Drug Sensitivity.
Xiong Z; Li X; Yin S; Xie M; Mao C; Zhang F; Chen H; Jin L; Lian L
Front Mol Biosci; 2021; 8():724889. PubMed ID: 34712696
[No Abstract] [Full Text] [Related]
14. A N6-methyladenosine-related long noncoding RNAs model for predicting prognosis in oral squamous cell carcinoma: Association with immune cell infiltration and tumor metastasis.
Yang Q; Cheng C; Zhu R; Guo F; Lai R; Liu X; Li M
Oral Oncol; 2022 Apr; 127():105771. PubMed ID: 35189585
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma.
Yuan Q; Ren J; Li L; Li S; Xiang K; Shang D
Bioengineered; 2021 Dec; 12(1):2432-2448. PubMed ID: 34233576
[TBL] [Abstract][Full Text] [Related]
16. The development and validation of a m6A-lncRNAs based prognostic model for overall survival in lung squamous cell carcinoma.
Huang H; Wu W; Lu Y; Pan X
J Thorac Dis; 2022 Oct; 14(10):4055-4072. PubMed ID: 36389308
[TBL] [Abstract][Full Text] [Related]
17. Identification of an m6A-related lncRNA prognostic signature in colorectal cancer.
Shi ZL; Yang X; Shen CL; Zhou GQ
J Biochem Mol Toxicol; 2023 Jan; 37(1):e23239. PubMed ID: 36205301
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
Song Y; Qu H
BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
[TBL] [Abstract][Full Text] [Related]
19. N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of Asian gastric cancer patients.
Xu S; Chen W; Wang Y; Zhang Y; Xia R; Shen J; Gong X; Liang Y; Xu J; Tang H; Zhao T; Zhang Y; Chen T; Wang C
BMC Cancer; 2022 Jul; 22(1):721. PubMed ID: 35778697
[TBL] [Abstract][Full Text] [Related]
20. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]